Iquix

Plague, Yersinia pestis, inhaled anthrax caused by Bacillus anthracis + 21 more

Treatment

1 FDA approval

3 Active Studies for Iquix

What is Iquix

Levofloxacin

The Generic name of this drug

Treatment Summary

Levofloxacin is an antibiotic used to treat various bacterial infections. It is 8 to 128 times more effective against both gram-negative and gram-positive bacteria than its predecessor, ofloxacin. This medication is a part of the third generation of fluoroquinolones, which are often referred to as "respiratory quinolones" due to their effectiveness in treating respiratory infections. Levofloxacin was approved by the FDA in 1996 and is also available in Canada and other South American countries.

Levaquin

is the brand name

image of different drug pills on a surface

Iquix Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Levaquin

Levofloxacin

1996

421

Approved as Treatment by the FDA

Levofloxacin, also known as Levaquin, is approved by the FDA for 1 uses like Pseudomonas Infections .

Pseudomonas Infections

Used to treat Nosocomial Pneumonia caused by Pseudomonas Infections in combination with Piperacillin

Effectiveness

How Iquix Affects Patients

Levofloxacin is an antibiotic that works by blocking the bacteria's ability to make new DNA, which stops it from reproducing. This drug usually requires only one or two doses a day, but can cause an abnormal heart rhythm in some patients, so it should be used carefully in people with other risk factors, like low potassium levels. It has been found to work against certain types of bacteria, as well as some other kinds of germs like Chlamydia and Legionella. It is possible for bacteria to become resistant to levofloxacin, but it is unlikely to become resistant to other kinds of antibiotics.

How Iquix works in the body

Levofloxacin is an antibiotic that fights bacteria by blocking two bacterial enzymes. These enzymes, called DNA gyrase and topoisomerase IV, help bacteria reproduce and survive. Levofloxacin stops these enzymes from working, which prevents the bacteria from dividing and growing. This leads to the death of the bacteria.

When to interrupt dosage

The measure of Iquix is contingent upon the recognized ailment, including Pseudomonas Infections, Abscess and Therapeutic process. The amount of dosage is contingent upon the technique of delivery outlined in the table below.

Condition

Dosage

Administration

Yersinia pestis

250.0 mg, 500.0 mg, 750.0 mg, , 5.0 mg/mL, 25.0 mg/mL, 15.0 mg/mL, 7.5 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 240.0 mg, 240.0 mg/mL

, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops - Ophthalmic, Solution / drops, Solution, Solution - Oral, Injection - Intravenous, Injection, Solution - Ophthalmic, Ophthalmic, Solution - Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Solution / drops - Topical, Respiratory (inhalation), Solution - Respiratory (inhalation), Topical

Cystic Fibrosis

250.0 mg, 500.0 mg, 750.0 mg, , 5.0 mg/mL, 25.0 mg/mL, 15.0 mg/mL, 7.5 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 240.0 mg, 240.0 mg/mL

, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops - Ophthalmic, Solution / drops, Solution, Solution - Oral, Injection - Intravenous, Injection, Solution - Ophthalmic, Ophthalmic, Solution - Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Solution / drops - Topical, Respiratory (inhalation), Solution - Respiratory (inhalation), Topical

Pseudomonas Infections

250.0 mg, 500.0 mg, 750.0 mg, , 5.0 mg/mL, 25.0 mg/mL, 15.0 mg/mL, 7.5 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 240.0 mg, 240.0 mg/mL

, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops - Ophthalmic, Solution / drops, Solution, Solution - Oral, Injection - Intravenous, Injection, Solution - Ophthalmic, Ophthalmic, Solution - Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Solution / drops - Topical, Respiratory (inhalation), Solution - Respiratory (inhalation), Topical

Impetigo

250.0 mg, 500.0 mg, 750.0 mg, , 5.0 mg/mL, 25.0 mg/mL, 15.0 mg/mL, 7.5 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 240.0 mg, 240.0 mg/mL

, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops - Ophthalmic, Solution / drops, Solution, Solution - Oral, Injection - Intravenous, Injection, Solution - Ophthalmic, Ophthalmic, Solution - Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Solution / drops - Topical, Respiratory (inhalation), Solution - Respiratory (inhalation), Topical

Wound Infection

250.0 mg, 500.0 mg, 750.0 mg, , 5.0 mg/mL, 25.0 mg/mL, 15.0 mg/mL, 7.5 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 240.0 mg, 240.0 mg/mL

, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops - Ophthalmic, Solution / drops, Solution, Solution - Oral, Injection - Intravenous, Injection, Solution - Ophthalmic, Ophthalmic, Solution - Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Solution / drops - Topical, Respiratory (inhalation), Solution - Respiratory (inhalation), Topical

Community Acquired Pneumonia (CAP) caused by susceptible bacteria

250.0 mg, 500.0 mg, 750.0 mg, , 5.0 mg/mL, 25.0 mg/mL, 15.0 mg/mL, 7.5 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 240.0 mg, 240.0 mg/mL

, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops - Ophthalmic, Solution / drops, Solution, Solution - Oral, Injection - Intravenous, Injection, Solution - Ophthalmic, Ophthalmic, Solution - Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Solution / drops - Topical, Respiratory (inhalation), Solution - Respiratory (inhalation), Topical

furuncle

250.0 mg, 500.0 mg, 750.0 mg, , 5.0 mg/mL, 25.0 mg/mL, 15.0 mg/mL, 7.5 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 240.0 mg, 240.0 mg/mL

, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops - Ophthalmic, Solution / drops, Solution, Solution - Oral, Injection - Intravenous, Injection, Solution - Ophthalmic, Ophthalmic, Solution - Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Solution / drops - Topical, Respiratory (inhalation), Solution - Respiratory (inhalation), Topical

Pyoderma

250.0 mg, 500.0 mg, 750.0 mg, , 5.0 mg/mL, 25.0 mg/mL, 15.0 mg/mL, 7.5 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 240.0 mg, 240.0 mg/mL

, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops - Ophthalmic, Solution / drops, Solution, Solution - Oral, Injection - Intravenous, Injection, Solution - Ophthalmic, Ophthalmic, Solution - Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Solution / drops - Topical, Respiratory (inhalation), Solution - Respiratory (inhalation), Topical

Hospital acquired pneumonia

250.0 mg, 500.0 mg, 750.0 mg, , 5.0 mg/mL, 25.0 mg/mL, 15.0 mg/mL, 7.5 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 240.0 mg, 240.0 mg/mL

, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops - Ophthalmic, Solution / drops, Solution, Solution - Oral, Injection - Intravenous, Injection, Solution - Ophthalmic, Ophthalmic, Solution - Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Solution / drops - Topical, Respiratory (inhalation), Solution - Respiratory (inhalation), Topical

Communicable Diseases

250.0 mg, 500.0 mg, 750.0 mg, , 5.0 mg/mL, 25.0 mg/mL, 15.0 mg/mL, 7.5 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 240.0 mg, 240.0 mg/mL

, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops - Ophthalmic, Solution / drops, Solution, Solution - Oral, Injection - Intravenous, Injection, Solution - Ophthalmic, Ophthalmic, Solution - Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Solution / drops - Topical, Respiratory (inhalation), Solution - Respiratory (inhalation), Topical

Cellulitis

250.0 mg, 500.0 mg, 750.0 mg, , 5.0 mg/mL, 25.0 mg/mL, 15.0 mg/mL, 7.5 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 240.0 mg, 240.0 mg/mL

, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops - Ophthalmic, Solution / drops, Solution, Solution - Oral, Injection - Intravenous, Injection, Solution - Ophthalmic, Ophthalmic, Solution - Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Solution / drops - Topical, Respiratory (inhalation), Solution - Respiratory (inhalation), Topical

Abscess

250.0 mg, 500.0 mg, 750.0 mg, , 5.0 mg/mL, 25.0 mg/mL, 15.0 mg/mL, 7.5 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 240.0 mg, 240.0 mg/mL

, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops - Ophthalmic, Solution / drops, Solution, Solution - Oral, Injection - Intravenous, Injection, Solution - Ophthalmic, Ophthalmic, Solution - Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Solution / drops - Topical, Respiratory (inhalation), Solution - Respiratory (inhalation), Topical

Prostatitis

250.0 mg, 500.0 mg, 750.0 mg, , 5.0 mg/mL, 25.0 mg/mL, 15.0 mg/mL, 7.5 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 240.0 mg, 240.0 mg/mL

, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops - Ophthalmic, Solution / drops, Solution, Solution - Oral, Injection - Intravenous, Injection, Solution - Ophthalmic, Ophthalmic, Solution - Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Solution / drops - Topical, Respiratory (inhalation), Solution - Respiratory (inhalation), Topical

Pseudomonas Infections

250.0 mg, 500.0 mg, 750.0 mg, , 5.0 mg/mL, 25.0 mg/mL, 15.0 mg/mL, 7.5 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 240.0 mg, 240.0 mg/mL

, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops - Ophthalmic, Solution / drops, Solution, Solution - Oral, Injection - Intravenous, Injection, Solution - Ophthalmic, Ophthalmic, Solution - Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Solution / drops - Topical, Respiratory (inhalation), Solution - Respiratory (inhalation), Topical

Communicable Diseases

250.0 mg, 500.0 mg, 750.0 mg, , 5.0 mg/mL, 25.0 mg/mL, 15.0 mg/mL, 7.5 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 240.0 mg, 240.0 mg/mL

, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops - Ophthalmic, Solution / drops, Solution, Solution - Oral, Injection - Intravenous, Injection, Solution - Ophthalmic, Ophthalmic, Solution - Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Solution / drops - Topical, Respiratory (inhalation), Solution - Respiratory (inhalation), Topical

Sinusitis

250.0 mg, 500.0 mg, 750.0 mg, , 5.0 mg/mL, 25.0 mg/mL, 15.0 mg/mL, 7.5 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 240.0 mg, 240.0 mg/mL

, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops - Ophthalmic, Solution / drops, Solution, Solution - Oral, Injection - Intravenous, Injection, Solution - Ophthalmic, Ophthalmic, Solution - Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Solution / drops - Topical, Respiratory (inhalation), Solution - Respiratory (inhalation), Topical

Urinary tract infection

250.0 mg, 500.0 mg, 750.0 mg, , 5.0 mg/mL, 25.0 mg/mL, 15.0 mg/mL, 7.5 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 240.0 mg, 240.0 mg/mL

, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops - Ophthalmic, Solution / drops, Solution, Solution - Oral, Injection - Intravenous, Injection, Solution - Ophthalmic, Ophthalmic, Solution - Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Solution / drops - Topical, Respiratory (inhalation), Solution - Respiratory (inhalation), Topical

Bacterial conjunctivitis

250.0 mg, 500.0 mg, 750.0 mg, , 5.0 mg/mL, 25.0 mg/mL, 15.0 mg/mL, 7.5 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 240.0 mg, 240.0 mg/mL

, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops - Ophthalmic, Solution / drops, Solution, Solution - Oral, Injection - Intravenous, Injection, Solution - Ophthalmic, Ophthalmic, Solution - Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Solution / drops - Topical, Respiratory (inhalation), Solution - Respiratory (inhalation), Topical

Therapeutic procedure

250.0 mg, 500.0 mg, 750.0 mg, , 5.0 mg/mL, 25.0 mg/mL, 15.0 mg/mL, 7.5 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 240.0 mg, 240.0 mg/mL

, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops - Ophthalmic, Solution / drops, Solution, Solution - Oral, Injection - Intravenous, Injection, Solution - Ophthalmic, Ophthalmic, Solution - Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Solution / drops - Topical, Respiratory (inhalation), Solution - Respiratory (inhalation), Topical

Plague

250.0 mg, 500.0 mg, 750.0 mg, , 5.0 mg/mL, 25.0 mg/mL, 15.0 mg/mL, 7.5 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 240.0 mg, 240.0 mg/mL

, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops - Ophthalmic, Solution / drops, Solution, Solution - Oral, Injection - Intravenous, Injection, Solution - Ophthalmic, Ophthalmic, Solution - Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Solution / drops - Topical, Respiratory (inhalation), Solution - Respiratory (inhalation), Topical

Warnings

Iquix has one contraindication, so its use should be avoided when faced with the conditions indicated in the table below.

Iquix Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Levofloxacin may interact with Pulse Frequency

There are 20 known major drug interactions with Iquix.

Common Iquix Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The excretion of Abemaciclib can be decreased when combined with Levofloxacin.

Amiodarone

Major

The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Amiodarone.

Amitriptyline

Major

Levofloxacin may increase the QTc-prolonging activities of Amitriptyline.

Anagrelide

Major

The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Anagrelide.

Arsenic trioxide

Major

The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Arsenic trioxide.

Iquix Toxicity & Overdose Risk

Levofloxacin is low in toxicity, yet an overdose can lead to ataxia, drooping eyelids, decreased movement, difficulty breathing, shaking, and seizures. Treatment for an overdose should include emptying the stomach and providing supportive care. It may also be helpful to monitor the patient's heart rate and rhythm. Dialysis is not an effective way to remove levofloxacin from the body.

Iquix Novel Uses: Which Conditions Have a Clinical Trial Featuring Iquix?

Condition

Clinical Trials

Trial Phases

Bronchitis

0 Actively Recruiting

Wound Infection

0 Actively Recruiting

inhaled anthrax caused by Bacillus anthracis

0 Actively Recruiting

Prostatitis

0 Actively Recruiting

Cellulitis

0 Actively Recruiting

Pseudomonas Infections

0 Actively Recruiting

Pseudomonas Infections

0 Actively Recruiting

Communicable Diseases

0 Actively Recruiting

Urinary tract infection

0 Actively Recruiting

Hospital acquired pneumonia

0 Actively Recruiting

Sinusitis

1 Actively Recruiting

Not Applicable

Yersinia pestis

0 Actively Recruiting

Plague

0 Actively Recruiting

Communicable Diseases

0 Actively Recruiting

Pyoderma

2 Actively Recruiting

Phase 2

Impetigo

0 Actively Recruiting

furuncle

0 Actively Recruiting

Community Acquired Pneumonia (CAP) caused by susceptible bacteria

0 Actively Recruiting

Urinary tract infection

0 Actively Recruiting

Communicable Diseases

0 Actively Recruiting

Iquix Reviews: What are patients saying about Iquix?

5

Patient Review

5/22/2008

Iquix for Ulcer of the Cornea of the Eye with Bacterial Infection

I had an infection in the back of my eye. The symptoms were gone in one day.

1

Patient Review

11/22/2009

Iquix for Ulcer of the Cornea of the Eye with Bacterial Infection

I've been using this medication for three weeks now, and I'm not seeing any results. I have a parasite in my eye and I wonder if there's something else out there that could help me.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about iquix

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is levofloxacin eye drops used for?

"Ophthalmic levofloxacin is used in the eye to treat bacterial infections of the eye. Ophthalmic levofloxacin works by killing bacteria. This medicine is available only with a prescription from your doctor."

Answered by AI

Is levaquin isotonic?

"This is a dilute solution of levofloxacin in 5% dextrose solution. It is non-pyrogenic and nearly isotonic."

Answered by AI

How to use eye drops?

"To use eye drops correctly, tilt your head back and look up. Use one hand to pull your lower eyelid down and away from your eyeball. This will form a pocket. Hold the eye drop bottle upside down in the other hand with the tip just above the pocket. Squeeze the prescribed number of drops into the pocket."

Answered by AI

Clinical Trials for Iquix

Image of Vancouver General Hospital in Vancouver, Canada.

In-Clinic Endoscopic Polypectomy for Nasal Polyps

18+
All Sexes
Vancouver, Canada

Chronic rhinosinusitis, also called chronic sinusitis, is a very common life-long disease affecting over 5% of the Canadian population. Its symptoms, including daily facial pain and headache, an inability to breath through the nose and complete smell loss, regularly impair one's ability to work and to enjoy and participate in daily activities. The annual cost of chronic sinusitis to Canada is estimated at $1.3 billion while the government pays an estimated $860 million yearly for chronic sinusitis treatment. Chronic sinusitis with polyps, the most common type of chronic sinusitis, is usually treated with a combination of medications and surgery. Until now, surgical treatment has only been performed in the operating room, at a cost of about $3500 per procedure. But, recent studies have shown that a new procedure, "in-clinic polyp removal", can provide an improvement in patient symptoms to levels equal to those for sinus surgery performed in a hospital operating room. Moreover, in clinic polyp removal has additional advantages including a shorter procedure recovery time, a significantly lower cost to the health care system (about one-tenth the cost or $450), and a shorter wait time for treatment. With the proposed pragmatic trial, the investigators will determine whether the in clinic polyp removal procedure is as good as sinus surgery in the operating room at controlling patient symptoms of chronic sinusitis. The investigators will also determine the cost and health-benefits for a patient, the healthcare system and for society of in clinic polyp removal in comparison to sinus surgery done in a hospital operating room. The investigators will then know if this new treatment, in clinic polyp removal, can replace sinus surgery as the standard of care for these patients.

Recruiting
Has No Placebo

Vancouver General Hospital (+4 Sites)

Shaun Kilty, MD

Medtronic